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Effects of Novel Chalcone Derivatives upon 
H9c2 and MDCK Cell Viability 
Introduction 
	
The characteristic 3’4’5’-trimethoxy aromatic ring from Combretastatin A-4 has been utilised in 
many chalcone (1,3-diphenyl-2-propen-1-one) derivatives to produce promising anticancer 
activity1 of which one is DMU-135 pro drug.. A group of halogenated methoxy based chalcone 
analogues (Mk 25, Mk 33, Mk 34 and Mk 35) were synthesised and designed based on the 
DMU-135 pro drug (3,4-Methylenedioxy-3',4',5'-trimethoxy chalcone), with the aim of 
developing potential new pharmaceutical agents.  
Despite their observed efficacy2, many chalcone-based drug discovery studies have not 
addressed cardiovascular toxicity.  However, this is a significant adverse effect associated with 
many anticancer drugs. We looked at the effects of novel chalcone derivatives upon MTT 
reduction using H9c2 and MDCK cell lines as models of cardiac and renal cells, respectively.   
 
	
Abstract  
 
Many compounds with potential anti-cancer activity fail to reach the latter stages of clinical trials due to adverse effects, often causing cardiac and renal toxicity. Here, we synthesised a group of 
novel chalcone compounds, thought to have potential anti-cancer activity4	 	and assessed their effects upon cardiac and renal cell viability. Data revealed that all compounds produced minimal 
short term toxicity. Further work will be performed to assess the long term effects of these compounds on cell viability, leading to mechanistic studies and structure activity relationship analyses.  
Materials and Methods 
 
Synthesis: Potassium Hydroxide 3 ml (20% w/v solution) was added to a mixture of 3’4’5’-
trimethoxyacetophenone (5 mmol) and aryl aldehyde (5 mmol) dissolved in 9 ml of ethanol. The 
mixture was stirred at room temperature for 1 hour monitored by thin layer chromatography. 
The precipitate formed was filtered off and washed with 2x 30ml water and 2x 30ml cold 
ethanol. Purification via ethanol recrystallization was used to produce pure chalcone which was 
verified by MS and NMR.  Mass spectra were recorded on a Thermo Scientific LTQ Orbitrap XL 
low resolution triple quadropole mass spectrometer (EPSRC National Mass Spectrometry 
Service Centre, Swansea UK). The 1H NMR and 13C NMR spectra were recorded on a Bruker 
Avance AV400 NMR spectrometer at 30oC. Tetramethylsilane was used as an internal 
standard.   
 
MTT assay: H9c2 and MDCK cells were cultured in complete Dulbecco’s Modified Eagle’s 
Medium (DMEM) and maintained in a gassed incubator (37°C, 95% air/5% CO2). For 
experiments, cells were seeded into 96-well plates (5000 cells/well) and, 24 hours later, treated 
with novel compounds (2 hours incubation at 37°C, 3-1000 µM in serum-free DMEM). Cell 
viability was assessed by the colorimetric conversion of 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) to purple formazan product (measured at 560 nm using a 
GloMax plate reader, Promega).  
 
Data analysis: Data were analysed using SigmaPlot 13.  Statistical significance was 
determined by ANOVA with a post hoc Tukey's test.  P < 0.05 was considered statistically 
significant. All data are presented as means ± S.E.M. The n in the text refers to the number of 
separate experiments, each performed in triplicate. 
 
 
 Results 
 
Mk 25:, pale yellow powder, yield 82%, m.p 106-110oC, TLC: Rf. = 0.25 (Hexane/Ethyl Acetate 
8:2); Mw 332.5;  MS, m/z [El+, %] 333.0890 (M+1, 100%) ; 1H NMR (DMSO-d6, 400 MHz): δ 
3.78 (3H, s, OCH3), 3.90 (6H, s, OCH3), 7.44 (2H, s, ArH), 7.46-7.50 (2H, m, ArH), 7.56-7.60 
(1H, m, ArH), 7.97 (1H, d, J = 15.7 Hz, C=CH), 7.85 (1H, d, J = 15.7 Hz, C=CH), 8.21-8.24 (1H, 
m, ArH); 13C NMR (DMSO-d6) δ 56.2, 60.2, 106.3, 124.6, 127.6, 128.7, 129.9, 131.9, 132.3, 
132.6, 134.6, 138.4, 142.2, 152.9, 187.8.  
 
Mk 33: pale yellow powder, yield 81%, m.p 136-139oC, TLC: Rf. = 0.29 (Hexane/Ethyl Acetate 
8:2); Mw 367.0; MS, m/z [El+, %] 367.0501 (M+1, 100%) ; 1H NMR (DMSO-d6, 400 MHz): δ 
3.78 (3H, s, OCH3), 3.91 (6H, s, OCH3), 7.44 (2H, s, ArH), 7.71 (1H, d, J = 15.2 Hz, C=CH), 
7.74 (1H, d, J = 7.1 Hz, ArH), 7.91 (1H, dd, J = 7.1, 2.0 Hz, ArH), 8.02 (1H, d, J = 15.2 Hz, 
C=CH), 8.25 (1H, d, J = 2.0 Hz, ArH); 13C NMR (DMSO-d6) δ 56.3, 60.2, 106.4, 123.6, 129.1, 
130.3, 130.4, 131.8, 132.6, 132.7, 135.5, 141.1, 142.2, 152.9, 187.7. 
  
Mk 34: pale yellow powder, yield 83%, m.p 110-115oC, TLC: Rf. = 0.25 (Hexane/Ethyl Acetate 
8:2); Mw 332.5; MS, m/z [El+, %] 333.0882 (M+1, 100%) ; 1H NMR (DMSO-d6, 400 MHz): δ 
3.77 (3H, s, OCH3), 3.91 (6H, s, OCH3), 7.44 (2H, s, ArH), 7.49-7.52 (2H, m, ArH), 7.72 (1H, d, 
J = 16.0 Hz, C=CH), 7.84-7.87 (1H, m, ArH), 8.01 (1H, d, J = 16.0 Hz, C=CH), 8.05 (1H, s, 
ArH); 13C NMR (DMSO-d6) δ 56.3, 60.2, 106.3, 123.3, 127.8, 128.1, 130.1, 132.7, 133.7, 
136.9, 142.2, 142.3, 152.9, 187.8. 
 
Mk 35: pale yellow powder, yield 70% m.p 115-119oC, TLC: Rf. = 0.25 (Hexane/Ethyl Acetate 
8:2); Mw  332.5; MS, m/z [El+, %] 333.0882 (M+1, 100%) ; 1H NMR (DMSO-d6, 400 MHz): δ 
3.77 (3H, s, OCH3), 3.90 (6H, s, OCH3), 7.43 (2H, s, ArH), 7.53 (2H, d, J = 8.5 Hz, ArH), 7.73 
(1H, d, J = 15.3 Hz, C=CH), 7.95 (2H, d, J = 8.5 Hz, ArH), 7.96 (1H, d, J = 15.3 Hz, C=CH); 13C 
NMR (DMSO-d6) δ 56.2, 60.2, 106.2, 122.5, 128.9, 130.7, 132.8, 133.6, 135.1, 142.0, 142.4, 
152.9, 187.8.  
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Figure 1: All four compounds are halogenated 
derivatives of this 3’4’5’-trimethoxy based 
chalcone analogue from DMU-135.  
Conclusion 
 
Data revealed that despite all four compounds showing concentration dependent inhibition of 
cell viability, significant inhibition was only observed at very concentrated level of 10 uM or 
higher. This suggests that these compounds exert minimal short term toxicity upon these cell 
lines. Further long term and mechanistic studies on cancer and endothelial cell lines will help to 
uncover any anti-cancer activity these compounds may possess. 
Figure 2: Mk33 compound appearing 
as a pale yellow powder 
MTT assay:  
All four chalcone compounds produced concentration-dependent inhibition of cell viability, as 
measured by MTT reduction in Hc92 (n=4) and MDCK (n=5).  * indicates significance (P < 
0.05) vs. control (i.e. untreated cells, 100%.viability). See figure 3A-D. 
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Figure 3: MDCK and H9c2 cells were exposed to novel compounds Mk25 (A), Mk 33 (B), Mk 
34 (C) or Mk35 (D) for 2 hrs, then cell viability was measured using the MTT assay.  Data 
shown as mean ± SEM.  For MDCK data n=5, for H9c2 cells n=4; each experiment performed 
in triplicate * = P < 0.05 vs. untreated controls (100% viability). 
